<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875131</url>
  </required_header>
  <id_info>
    <org_study_id>1050545</org_study_id>
    <nct_id>NCT03875131</nct_id>
  </id_info>
  <brief_title>Definition, Quantification, and Utility of Biomarkers of Repetitive Brain Injury in Predicting Concussion and Other Long-Term Injury Risks in Patients With Atrial Fibrillation (Concussion AF)</brief_title>
  <acronym>Concussion AF</acronym>
  <official_title>Definition, Quantification, and Utility of Biomarkers of Repetitive Brain Injury in Predicting Concussion and Other Long-Term Injury Risks in Patients With Atrial Fibrillation (Concussion AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intermountain Health Care, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective clinical study designed to evaluate biomarkers of brain injury and
      dementia incidence and moderate cognitive decline rates in moderate- to high-risk atrial
      fibrillation patients that undergo standard of care atrial fibrillation management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A written informed consent will be obtained from atrial fibrillation patients seen at
      Intermountain Medical Center who meet the study eligibility criteria. Following the baseline
      visit for obtaining informed consent and conduct of baseline procedures, subjects will be
      required to return to clinic at 6, 12, 18 and 24 months after enrollment. Cognitive testing
      will be performed at baseline and repeated at 24 months. As much as possible, the study
      follow-up visits will be scheduled at the same time as the patients' regular visits for
      clinical care.

      Six questionnaires will be administered at the baseline visit and repeated at the 24-month
      visit. At the time of cognitive assessment, the following will be completed, if not already
      performed as part of usual standard of care: complete blood count, protime/INR, basic
      metabolic profile, review of cardiac medications, and review of adverse events and
      hospitalizations. Additional serum tests will be performed on all subjects at enrollment and
      at the 24-month visit. Biomarkers will be drawn at specific intervals (baseline, 6, 12, 18,
      and 24 months) then on an as needed basis (within 7 days) when treatments for atrial
      fibrillation that may increase brain injury risk occur.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 15, 2017</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incident dementia based on the Mini-Mental Status Examination</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Mini-Mental Status Examination will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://www.dhs.state.mn.us/main/groups/county_access/documents/pub/dhs16_159601.pdf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident dementia based on the Hachinski Ischemic Scale</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Hachinski Ischemic Scale will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://www.strokecenter.org/wp-content/uploads/2011/08/hachinski.pdf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident dementia based on the Cognitive Subscale of Alzheimer's Disease Assessment Scale</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Cognitive Subscale of Alzheimer's Disease Assessment Scale will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://www.adcs.org/Industry/instruments.aspx.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident dementia based on the Disability Assessment for Dementia</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Disability Assessment for Dementia will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://www.statisticssolutions.com/disability-assessment-for-dementia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident dementia based on the Minnesota Living with Heart Failure Scale</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Minnesota Living with Heart Failure Scale will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://www.queri.research.va.gov/chf/products/hf_toolkit/Minnesota-HF-Questionnaire_Rector.pdf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident dementia based on the Anti-Clot Treatment Scale (ACTS) Quality of Life Survey</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Anti-Clot Treatment Scale (ACTS) Quality of Life Survey will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://hqlo.biomedcentral.com/articles/10.1186/1477-7525-10-120.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Moderate change in cognitive decline based on Mini-Mental Status Examination</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Mini-Mental Status Examination will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://www.dhs.state.mn.us/main/groups/county_access/documents/pub/dhs16_159601.pdf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate change in cognitive decline based on Hachinski Ischemic Scale</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Hachinski Ischemic Scale will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://www.strokecenter.org/wp-content/uploads/2011/08/hachinski.pdf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate change in cognitive decline based on Cognitive Subscale of Alzheimer's Disease Assessment Scale</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Cognitive Subscale of Alzheimer's Disease Assessment Scale will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://www.adcs.org/Industry/instruments.aspx.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate change in cognitive decline based on Disability Assessment for Dementia</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Disability Assessment for Dementia will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://www.statisticssolutions.com/disability-assessment-for-dementia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate change in cognitive decline based on Minnesota Living with Heart Failure Scale</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Minnesota Living with Heart Failure Scale will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://www.queri.research.va.gov/chf/products/hf_toolkit/Minnesota-HF-Questionnaire_Rector.pdf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate change in cognitive decline based on Anti-Clot Treatment Scale (ACTS) Quality of Life Survey</measure>
    <time_frame>24 months</time_frame>
    <description>For cognitive assessment, the Anti-Clot Treatment Scale (ACTS) Quality of Life Survey will be administered at the baseline visit and repeated at the 24-month visits. More information can be obtained at http://hqlo.biomedcentral.com/articles/10.1186/1477-7525-10-120.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cognitive Change</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarkers of Dementia and Cognitive Decline</intervention_name>
    <description>Biomarkers will be obtained at baseline, 6, 12, 18, and 24 months.
The six questionnaires listed below will be administered at the baseline visit, and repeated at the 24-month visit to evaluate cognitive decline.
Mini-Mental Status Evaluation
Hachinski Ischemic Scale
Cognitive Subscale of Alzheimer's Disease Assessment Scale
Disability Assessment for dementia
Quality of life improvement as assessed by:
Minnesota Living with Heart Failure Scale
Anti-Clot Treatment Scale (ACTS) Quality of Life Survey</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At each visit a blood sample of 16 mL will be collected for standard blood tests at
      enrollment, 6,12, 18, and 24 months. Additionally, blood samples will be collected (12 mL)
      and tested for biomarkers at the time of enrollment, follow-up visits at 6, 12, 18 and 24
      months after enrollment. The research staff will keep a portion of the blood that can be used
      for a future study and it will be maintained in the Intermountain biological specimen
      repository. Biological samples may be used in current and future research tests multiple
      times, or until the sample is consumed.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Moderate- to high-risk atrial fibrillation patients that undergo standard of care atrial
        fibrillation management at Intermountain Medical Center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 65 to â‰¤ 95 years of age

          2. Ability to understand and sign a written informed consent form, which must be obtained
             prior to initiation of any study procedures

          3. AF documented by electrocardiogram, ambulatory event monitor, telemetry, or medical
             records within 12 months of enrollment

          4. Ability to complete a mini-mental status evaluation

          5. Ability to independently comprehend and complete a quality of life and dementia
             questionnaires

          6. Willing and able to comply with the follow-up visits, tests, and schedule of
             evaluations

        Exclusion Criteria:

          1. Have a history of any form of dementia

          2. Have a life expectancy less than 24 months

          3. Participation in any other clinical trials involving investigational or marketed
             products within 30 days prior to entry in the study

          4. Other conditions that in the opinion of the Principal Investigator and/or
             Sub-Investigator(s) may increase risk to the subject and/or compromise the quality of
             the clinical trial

          5. The Principal Investigator and/or Sub-Investigator(s) determine(s) that the subject is
             not eligible for participation in this research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jared Bunch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>March 13, 2019</last_update_submitted>
  <last_update_submitted_qc>March 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

